Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphoma.

Item

http://www.wikidata.org/entity/Q38205923

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphoma.

@en

type

Item

label

Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphoma.

@en

prefLabel

Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphoma.

@en

P1476

Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphoma.

@en

P2093

Andreas Engert

http://www.w3.org/2001/XMLSchema#string

Dennis A Eichenauer

http://www.w3.org/2001/XMLSchema#string

P2860

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma.

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation

Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma.

cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.

Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG).

High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma.

P304

1-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/EJH.12347

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261769437

http://www.w3.org/2001/XMLSchema#string

P698

24750367

http://www.w3.org/2001/XMLSchema#string